Datapoint: Viatris Sells Biosimilar Business to Biocon

Viatris, the manufacturer of the first interchangeable biosimilar, on Monday revealed it will sell its biosimilar business to partner Biocon Biologics in a $3.3 billion deal. This includes Semglee, the insulin interchangeable with Sanofi’s Lantus. The drug launched in November 2021. For the treatment of type 2 diabetes, Semglee currently holds covered or better status for 59% of all insured lives, to Lantus’ 70%.

SOURCE: MMIT Analytics, as of 3/1/22

0 Comments
© 2025 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 17

Datapoint: Michigan Awards Contracts for New Duals Program

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 16

Datapoint: CMS Releases 2025 Star Ratings

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 15

Datapoint: Pfizer Scores Another Hemophilia Nod

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today